Signature Biologics has received clearance from the U.S. Food and Drug Administration for expanded enrollment under an Investigational New Drug application covering an investigational umbilical cord-derived mesenchymal stem cell therapy for Duchenne muscular dystrophy. Up to 30 additional participants may now be enrolled after an initial cohort of five, potentially increasing participation to 35, although the company has reported no efficacy results from the program and the therapy remains investigational.
The regulatory action is significant primarily because it permits treatment of a materially larger group, rather than because it establishes that the UC-MSC therapy works. Signature Biologics said the original five participants have completed enrollment, while recruitment of additional patients is expected to resume after another clinical site is activated. The Investigational New Drug application is held by the contracted clinical research organization serving as sponsor, while Signature Biologics manufactures the investigational cellular product and funds the program. ClinicalTrials.gov identifies MED Institute Inc. as the sponsor and Signature Biologics as a collaborator.
That distinction matters in Duchenne muscular dystrophy, where increasingly sophisticated genetic, pharmacological and cell-based approaches are being investigated against a progressively disabling disease. Duchenne is caused by mutations in the DMD gene that result in absent or dysfunctional dystrophin, leaving muscle fibers vulnerable to progressive damage. The condition primarily affects males and ultimately extends beyond skeletal muscle to cardiac and respiratory function.
What does the FDA expanded enrollment decision actually mean for the Signature Biologics DMD program?
The program, registered as NCT06579352, is formally described on ClinicalTrials.gov as an intermediate-size expanded access study of human umbilical cord mesenchymal stem cells in Duchenne muscular dystrophy. FDA regulations treat intermediate-size expanded access differently from a conventional clinical trial designed principally to establish efficacy for a marketing application. Expanded access is intended to provide investigational treatment to more than one patient, generally fewer than would participate in a widespread treatment protocol, when regulatory criteria for treatment access are satisfied.
For intermediate-size access, FDA guidance indicates that there must be enough evidence to justify exposure of the anticipated number of patients at the proposed dose and duration, along with at least preliminary clinical evidence of effectiveness or a plausible pharmacologic effect that makes the investigational product a reasonable therapeutic option for the relevant population. Those regulatory criteria are meaningful, but they should not be interpreted as the evidentiary standard required for approval or as confirmation that clinical benefit has been demonstrated.
Signature Biologics itself explicitly cautioned that the UC-MSC therapy has not been approved by the FDA or another regulatory authority and that its safety and effectiveness have not been established. The company also said no efficacy results from the current study were being reported and warned that observations from the initial small group should not be used to predict what may happen as enrollment expands.
The practical milestone, therefore, is scale. Moving from five treated participants toward a population of as many as 35 could generate a substantially larger safety and longitudinal observational dataset. It also creates a greater opportunity to examine whether functional measurements move consistently enough across participants to justify more formal clinical development, although the expanded-access design itself will impose limits on what can be concluded from those observations.
Which Duchenne patients are eligible and how is the UC-MSC treatment administered?
The ClinicalTrials.gov record describes the eligible population as ambulatory males aged five through 10 years with genetically confirmed Duchenne muscular dystrophy. Participants must meet specified functional criteria, including a North Star Ambulatory Assessment score above 13 and below 30 and the ability to complete a time-to-rise test in less than 10 seconds. Stable glucocorticoid treatment for at least 12 weeks is also among the eligibility requirements, while the record specifies that patients should be non-responders to or poor candidates for another established therapy.
The regimen involves intravenous administration of umbilical cord-derived mesenchymal stem cells. ClinicalTrials.gov describes four treatment cycles, each consisting of three days of intravenous dosing and administered at three-month intervals, with participants monitored longitudinally after treatment. The registered program therefore involves repeated exposure rather than a single administration, making cumulative tolerability and consistency across dosing cycles particularly important components of the eventual evidence package.
Signature Biologics said assessments include the 4 Stair Climb, 10-meter walk test and North Star Ambulatory Assessment, together with the PedsQL DMD Module, PedsQL Multidimensional Fatigue Scale, metabolic laboratory testing and inflammatory cytokine panels. These measures give investigators multiple ways of examining functional trajectory, patient-reported impact and biological changes, but a movement in any single measure would still need to be interpreted within the limitations of the study design.
The inclusion of North Star Ambulatory Assessment and timed functional measures places the program within a familiar DMD clinical measurement framework. Similar assessments have played important roles elsewhere in Duchenne drug development. For example, FDA’s evaluation of the gene therapy Elevidys included the North Star Ambulatory Assessment, time to rise from the floor, 10-meter walk or run and time to ascend four steps. That does not make results from separate products directly comparable, but it demonstrates why these measures are clinically relevant to ambulatory DMD development.
Why will the open-label and historically controlled design limit conclusions about efficacy?
Signature Biologics describes the program as open-label and historically controlled. There is no contemporaneous randomized placebo group disclosed in the company announcement, meaning any apparent functional stabilization or improvement would have to be interpreted against historical disease trajectories rather than a simultaneously enrolled control population.
That is an especially important limitation in Duchenne muscular dystrophy because motor performance changes with age, baseline disease severity and disease progression, while concomitant care can also influence observed trajectories. Even carefully matched historical controls cannot fully reproduce the balancing effect that randomization provides for measured and unmeasured differences between groups. An expanded cohort may reduce the instability associated with an extremely small sample, but increasing enrollment does not by itself eliminate design-related confounding.
The FDA has separately recognized the complexities of developing therapeutics for Duchenne and related dystrophinopathies, diseases characterized by progressive skeletal and cardiac muscle degeneration that ultimately affects muscle function, respiration and cardiac health. The regulatory challenge is consequently not simply to detect a numerical change in an assessment, but to establish that an observed treatment effect can credibly be attributed to the intervention and is clinically meaningful.
For Signature Biologics, that means future functional observations could be useful for hypothesis generation and for determining whether a larger controlled development program is justified. They would not automatically constitute confirmatory evidence simply because more participants have been treated.
How does UC-MSC therapy differ from other approaches being developed for Duchenne muscular dystrophy?
Umbilical cord-derived mesenchymal stem cell therapy represents a different biological strategy from therapies that directly target dystrophin production or specific DMD mutations. UC-MSC treatment does not function as an exon-skipping medicine or as the AAV gene-delivery approach used by Elevidys. The broader scientific interest in mesenchymal stromal and stem cells has included their potential regenerative, immunomodulatory and anti-inflammatory properties, but these biological hypotheses cannot substitute for evidence that a specific manufactured cell product produces durable functional benefit in patients with Duchenne. Research into stem and progenitor cell approaches remains an active component of the wider DMD pipeline.
The competitive clinical context has also changed markedly in recent years. Duchenne management now includes corticosteroid-based treatment, mutation-specific exon-skipping therapies, givinostat and gene therapy for eligible patients, alongside multidisciplinary cardiac, respiratory, rehabilitation and supportive care. The FDA approved givinostat for patients aged six years and older in 2024, while mutation-directed approaches serve narrower genetically defined groups.
Elevidys illustrates both the opportunities and the evidentiary challenges facing advanced therapies in Duchenne. Its current U.S. indication is limited to ambulatory patients aged four years and older with a confirmed DMD gene mutation. In November 2025, FDA revised the label to include a boxed warning for serious liver injury and acute liver failure, including fatal outcomes, and removed the previous indication for non-ambulatory patients.
Those developments should not be used to imply that an intravenously delivered UC-MSC product shares the same risk profile as an AAV gene therapy. The modalities are biologically different. They do, however, reinforce the broader requirement for long-term safety surveillance when advanced biological products are administered to children with a serious chronic disease.
Could a larger cohort provide a clearer picture of the UC-MSC therapy’s clinical potential?
Increasing the accessible population from five participants to as many as 35 could materially improve the amount of information available on repeated administration. An initial five-patient experience is highly vulnerable to individual variability, particularly when functional performance is being assessed in a progressive neuromuscular disease. A larger cohort can provide better visibility into the frequency of adverse events, treatment discontinuations, variability between patients and whether functional trajectories display any reproducible pattern.
The program could also produce useful information about manufacturing and delivery. Cell therapies depend not only on biological activity but on consistent cell sourcing, manufacturing controls, release specifications, storage, transport and administration across clinical sites. Signature Biologics is responsible for manufacturing the UC-MSC investigational product, meaning expansion beyond the initial cohort provides an operational test of whether the company can reproduce its manufacturing and treatment process across a larger population.
Still, commercial implications remain distant. Permission to enroll additional expanded-access patients is not equivalent to progressing into a pivotal registration trial, filing a Biologics License Application or securing FDA approval. Any eventual route toward broader development would require an evidence package appropriate to the intended regulatory pathway, together with sufficient manufacturing, safety and clinical data.
What are the key takeaways from the FDA decision for Signature Biologics?
The most important development is that the FDA has permitted the investigational program to move beyond its five-patient initial cohort and potentially treat up to 30 additional participants. Recruitment has not yet restarted because the sponsor is seeking another clinical site, while no efficacy results have been released. The UC-MSC product remains investigational, and the FDA decision should therefore be viewed as an expansion of permitted access and evidence generation rather than an endorsement of clinical benefit.
The larger cohort nevertheless creates a meaningful opportunity for Signature Biologics and MED Institute Inc. to generate more informative longitudinal safety and functional data than could be obtained from five participants alone. The most consequential questions will concern repeated-dose tolerability, consistency across functional assessments, durability of any observed changes and whether the findings are strong enough to justify a more rigorous controlled development program.
What should clinicians and the Duchenne research field watch as enrollment resumes?
The immediate milestone is relatively straightforward: Signature Biologics and the study sponsor need to activate another clinical site before recruitment of the newly permitted participants can resume. After that, attention is likely to shift from the size of the expanded-access population to the quality and maturity of the resulting evidence.
A persuasive next stage would require more than isolated improvements in individual patients. Investigators will need to understand adverse events across repeated dosing, the distribution of functional outcomes across the cohort, how those outcomes compare with expected disease progression, whether any biological changes align with functional observations and whether an effect, if observed, persists over meaningful follow-up. Publication or detailed scientific presentation of the data would also make independent interpretation substantially easier.
For now, the FDA decision gives Signature Biologics a larger clinical canvas on which to investigate its UC-MSC approach. The next test is substantially harder: showing whether observations from expanded access can produce a sufficiently coherent safety and activity signal to warrant a controlled development strategy capable of separating treatment effect from the natural variability of Duchenne muscular dystrophy.
